Slingshot members are tracking this event:
Xenon expects to identify a Nav1.6 sodium channel inhibitor for the treatment of rare infantile epileptic encephalopathies development candidate in 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|XENE||Community voting in process|
Xenon's development of a Nav1.6 sodium channel inhibitor for the treatment of rare infantile epileptic encephalopathies – such as Dravet Syndrome and SCN8A (Nav1.6 gain-of-function) Epilepsy – continues to progress well. Xenon has identified potent, selective Nav1.6 inhibitors, and encouraging results from in vivo animal studies indicate that selective Nav1.6 inhibitors have demonstrated efficacy for seizures in a model of Nav1.6 gain-of-function SCN8A epilepsy, supporting the hypothesis that SCN8A epilepsies can be treated with potent, selective Nav1.6 inhibitors. Xenon expects to identify a development candidate in 2016 and file an investigational new drug (IND) application in the first half of 2017.
Slingshot Insights Explained
Mar 08, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Nav1.6 Sodium Channel Inhibitor, Rare Infantile Epileptic Encephalopathies, Ind, Scn8a Epilepsies